Mera Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Fiscal Year	TTM	FY 2020	FY 2019	FY 2011	FY 2010	FY 2009	2012 - 2016
Period Ending	Jul '21 Jul 31, 2021	Oct '20 Oct 31, 2020	Oct '19 Oct 31, 2019	Oct '11 Oct 31, 2011	Oct '10 Oct 31, 2010	Oct '09 Oct 31, 2009	2012 - 2016
Net Income	-0.01	-0.01	-0.01	-0.19	-0.54	-0.19	Upgrade
Depreciation & Amortization	-	-	-	0.01	0.03	0.08	Upgrade
Asset Writedown & Restructuring Costs	-	-	-	-	0.31	0.02	Upgrade
Provision & Write-off of Bad Debts	-	-	-	0	-	-	Upgrade
Change in Accounts Receivable	-	-	-	0	-0	0	Upgrade
Change in Accounts Payable	0.01	0.01	0.01	0.11	0.21	0.03	Upgrade
Change in Unearned Revenue	-	-	-	-	-	0.03	Upgrade
Change in Other Net Operating Assets	-	-	-	-0.04	0.02	0	Upgrade
Operating Cash Flow	-	-	-	-0.07	0.01	-0.03	Upgrade
Capital Expenditures	-	-	-	-0	-0.15	-0.02	Upgrade
Investment in Securities	-	-	-	-	-	0.03	Upgrade
Investing Cash Flow	-	-	-	-0	-0.15	0.01	Upgrade
Short-Term Debt Issued	-	-	-	0.07	0.14	-	Upgrade
Total Debt Issued	-	-	-	0.07	0.14	-	Upgrade
Net Debt Issued (Repaid)	-	-	-	0.07	0.14	-	Upgrade
Financing Cash Flow	-	-	-	0.07	0.14	-	Upgrade
Net Cash Flow	-	-	-	-0	0	-0.02	Upgrade
Free Cash Flow	-	-	-	-0.07	-0.14	-0.05	Upgrade
Free Cash Flow Margin	-	-	-	-24.49%	-48.96%	-8.44%	Upgrade
Levered Free Cash Flow	-	-	-	-0.05	-0.08	0.02	Upgrade
Unlevered Free Cash Flow	-	-	-	-0.05	-0.08	0.03	Upgrade
Change in Working Capital	0.01	0.01	0.01	0.11	0.2	0.06	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.